# Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

> **NCT05588297** · PHASE2 · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Colorectal Cancer Liver Metastases

## Interventions

- **DRUG:** CapOx(Capecitabine+ Oxaliplatin)
- **DRUG:** Bevacizumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05588297
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2023-03
- **Final completion:** 2025-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05588297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05588297, "Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05588297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*